Article thumbnail

Data from: Nε-acetyl-lysine analogues with Zinc binding groups as novel HDAC inhibitors

By Fang Wang, Chun Wang, Jie Wang, Yefang Zou, Xiaoxue Chen, Ting Liu, Yan Li, Yonglong Zhao, Yongjun Li and He Bin


HDAC inhibitors have been developed very rapidly in clinical trials and even in approvals for treating several cancers. However, there are few reported HDAC inhibitors designed from Nε-acetyl lysine. In current study, we raised a novel design, which is about Nε-acetyl lysine analogues containing amide acetyl groups with the hybridization of ZBG groups as novel HDAC inhibitors

Topics: Life sciences, medicine and health care, Life sciences, medicine and health care
Publisher: Data Archiving and Networked Services (DANS)
DOI identifier: 10.5061/dryad.d1t59pp
OAI identifier:
Provided by: NARCIS
Download PDF:
Sorry, we are unable to provide the full text but you may find it at the following location(s):
  • (external link)
  • (external link)
  • Suggested articles

    To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.